Pay in 4 interest-free payments of $6.33 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
Dec 2017;34(12):1627-1632
Comparisons With Other Diabetes Therapies Putting GLP1s in context with other antidiabetic agents offers additional insights: Thiazolidinediones (TZDs) are associated with increased fracture risk, especially in women SGLT2 inhibitors have raised concerns in some trials, particularly canagliflozin DPP-4 inhibitors appear largely neutral regarding skeletal effects Against this backdrop, GLP1s may have a neutral or possibly safer profile, though the data are not conclusive
In addition to their significant A1C-lowering effects, the landmark clinical trials for these respective agents found substantial appetite suppression, less feeling of "reward" after eating, and subsequent weight loss
With injections, you get the drug once a week
Oncology is not a small commitment
US$ 22.66
US$ 28.27
US$ 26.28
US$ 20.42
US$ 23.85
US$ 27.65
US$ 27.23
US$ 23.19
US$ 22.60
US$ 24.91
